Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures
BD worked with JCI to create a Gold Standard benchmarked safety program called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME)
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
When the Delfi technology was used as a pre-screen to determine if a low dose CT (LDCT), should be performed, the combined approach led to the detection of 90% of lung cancers, including 80% of stage I cancers
Employees of QubeHealth’s corporate clients draw as much money as they need to instantly pay for any medical emergencies or regular healthcare payments
The vaccine will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of Covid-19 disease
New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
The company plans to invest in technology, business development, product innovation, and development across India
Subscribe To Our Newsletter & Stay Updated
